Search

Researchers discover that a subset of lung adenocarcinomas are aggressive because of mutations that allow them to block ferroptosis, a type of cell death.

… Tuesday, December 1, 2020 Summary An MSK team has found that a particular subset of lung adenocarcinomas is aggressive due to a combination of two mutations that allow them to block ferroptosis, a type of cell death. Targeted therapies are currently available for about one-third of people with lung adenocarcinoma

In our recently published review paper we provide a comprehensive update on the cardiotoxicities associated with contemporary breast cancer treatment and the latest strategies for their prevention, detection, and management.

… Friday, June 28, 2019 It is critical to balance the expected benefits of cancer treatment with cardiovascular risk and identify strategies to prevent cardiotoxicity and improve outcomes and the long-term quality of life for breast cancer survivors. In our review paper published recently in the journal

When considering adjuvant therapy preferences for younger patients ages 50 to 69 with early-stage, low genomic risk breast cancer, is it reasonable to omit radiotherapy or endocrine therapy after lumpectomy? A large retrospective cohort study at MSK found that locoregional recurrence rates were significantly lower for those who completed at least one form of adjuvant therapy after lumpectomy.

… Friday, October 10, 2025 When considering adjuvant therapy preferences for younger patients ages 50 to 69 with early-stage, low genomic risk breast cancer, is it reasonable to omit radiotherapy (RT) or endocrine therapy (ET) after lumpectomy? A large retrospective cohort study at MSK found that locoregional

Wider negative margins do not improve local control for ductal carcinoma in situ or invasive carcinoma when they are treated with lumpectomy and radiation therapy, our recent literature review shows.

… Monday, October 8, 2018 Wider negative margins do not improve local control for ductal carcinoma in situ or invasive carcinoma when they are treated with lumpectomy and radiation therapy, our recent literature review shows. However, ambiguity regarding margin width in such cases persists, leading to

Memorial Sloan Kettering Cancer Center, along with five other elite academic institutions, will share an unprecedented total of $540 million in new financial support from Ludwig Cancer Research.

… Monday, January 6, 2014 Ludwig Center at Memorial Sloan Kettering Receives $90 Million in Funding For Cancer Research Memorial Sloan Kettering Cancer Center, along with five other elite academic institutions, will share an unprecedented total of $540 million in new financial support from Ludwig Cancer

MSK experts discuss risk factors, symptoms, and treatment for male breast cancer.

… Monday, September 26, 2022 Breast cancer in men accounts for less than 1% of all cases of breast cancer . But because breast cancer is so common, that still amounts to about 2,700 cases in the United States every year. The current treatments for men with breast cancer are largely based on what doctors

Sequencing advanced endometrial tumors with the MSK-IMPACT™ assay provides an effective method for detecting microsatellite instability (MSI) and germline cancer predisposition syndromes

… Thursday, December 13, 2018 Sequencing advanced endometrial tumors with the MSK-IMPACT™ assay provides an effective method for detecting microsatellite instability (MSI) and germline cancer predisposition syndromes, which are collectively present in 16 percent of patients, as well as potentially actionable

New MSK research illuminates new details about Thetis cells that will support efforts to harness them therapeutically; shows how the timing and strength of danger signals steer immune cell fates; and employs single-nucleus DNA sequencing to shed new light on the evolution of pancreatic cancer.

… Wednesday, February 4, 2026   New research from Memorial Sloan Kettering Cancer Center (MSK) illuminates new details about Thetis cells that will support efforts to harness them therapeutically; shows how the timing and strength of danger signals steer immune cell fates; and employs single-nucleus DNA

Everolimus plus bevacizumab demonstrates robust activity in treatment-naïve patients with advanced papillary variant nonclear cell renal cell carcinoma.

… Monday, November 9, 2020 Everolimus plus bevacizumab demonstrates robust activity in treatment-naïve patients with advanced papillary variant nonclear cell renal cell carcinoma (nccRCC), according to the results of an expanded single-arm, single-institution phase II trial conducted at Memorial Sloan

Learn how to get enough calories during treatment from MSK specialists in diet and nutrition.

… Tuesday, January 15, 2019 Summary MSK experts offer tips on how people who are currently in cancer treatment can get enough vital calories when they need them most. During cancer treatment, many people face a nutritional double whammy. The disease can rob them of their appetite and sap their strength